Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid ...
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoi...
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
- Conditions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 288
- Registration Number
- NCT00097825
- Locations
- 🇺🇸
St. Joseph Hospital, Bangor, Maine, United States
🇺🇸Osteoporosis and Clinical Trials Center, Hagerstown, Maryland, United States
🇺🇸UC Bone Health and Osteoporosis Center, Cincinnati, Ohio, United States
Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid
- Conditions
- First Posted Date
- 2004-12-01
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT00097812
- Locations
- 🇺🇸
Arthritis Center of Nebraska, Lincoln, Nebraska, United States
🇺🇸University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇩🇪Novartis, Nuernberg, Germany
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2013-02-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 600
- Registration Number
- NCT00003884
- Locations
- 🇺🇸
Cancer Specialist of South Texas. P.A., Corpus Christi, Texas, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
🇺🇸American Medical Research Institute, Inc., Atlanta, Georgia, United States
A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy
- Conditions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00087659
- Locations
- 🇺🇸
Veterans Affairs Medical Center, Augusta, Georgia, United States
🇺🇸WJB Dorn Veteran Affairs Medical Center, Columbia, South Carolina, United States
🇺🇸West Sde Vamc, Chicago, Illinois, United States
Non-small Cell Lung Cancer Study US75 (Z-PACT)
- Conditions
- Interventions
- First Posted Date
- 2004-07-01
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 250
- Registration Number
- NCT00086268
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Advocate Illinois Masonic Medical Center Creticos Cancer Center, Chicago, Illinois, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
- Conditions
- First Posted Date
- 2004-06-18
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 544
- Registration Number
- NCT00005073
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00081159
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
🇺🇸M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 645
- Registration Number
- NCT00079001
- Locations
- 🇺🇸
Good Samaritan Hospital of Maryland, Baltimore, Maryland, United States
🇺🇸Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Fisher-Titus Medical Center, Norwalk, Ohio, United States
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- University of Sheffield
- Registration Number
- NCT00072020
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
- Conditions
- First Posted Date
- 2003-07-03
- Last Posted Date
- 2017-09-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00063609
- Locations
- 🇺🇸
Southeastern Urological Center, PA, Tallahassee, Florida, United States
🇺🇸Advanced Urology Med. Center, Anaheim, California, United States
🇺🇸Grove Hill Urology, New Britain, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.